Lanean...
New and emerging concepts in the use of denosumab for the treatment of osteoporosis
Denosumab is a fully human monoclonal antibody to receptor activator of nuclear factor kappa-B ligand (RANKL), a cytokine expressed by cells of the osteoblast lineage that is a key regulator of osteoclastic bone resorption. By binding and neutralizing RANKL, denosumab inhibits osteoclast differentia...
Gorde:
| Argitaratua izan da: | Ther Adv Musculoskelet Dis |
|---|---|
| Egile nagusia: | |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
SAGE Publications
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6204627/ https://ncbi.nlm.nih.gov/pubmed/30386439 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1759720X18805759 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|